1. Электронный научный архив УрФУ
  2. 00. Общеуниверситетские коллекции
  3. Научные публикации ученых УрФУ, проиндексированные в SCOPUS и WoS CC
Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на этот ресурс: http://elar.urfu.ru/handle/10995/101482
Полная запись метаданных
Поле DCЗначениеЯзык
dc.contributor.authorKanwugu, O. N.en
dc.contributor.authorAdadi, P.en
dc.date.accessioned2021-08-31T14:57:36Z-
dc.date.available2021-08-31T14:57:36Z-
dc.date.issued2021-
dc.identifier.citationKanwugu O. N. HIV/SARS-CoV-2 coinfection: A global perspective / O. N. Kanwugu, P. Adadi. — DOI 10.1002/jmv.26321 // Journal of Medical Virology. — 2021. — Vol. 93. — Iss. 2. — P. 726-732.en
dc.identifier.issn1466615-
dc.identifier.otherFinal2
dc.identifier.otherAll Open Access, Bronze, Green3
dc.identifier.otherhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85088583592&doi=10.1002%2fjmv.26321&partnerID=40&md5=9f4a9266fa950cc756211f3199df34ac
dc.identifier.otherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jmv.26321m
dc.identifier.urihttp://elar.urfu.ru/handle/10995/101482-
dc.description.abstractSince its first appearance in Wuhan, China, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread throughout the world and has become a global pandemic. Several medical comorbidities have been identified as risk factors for coronavirus disease 2019 (COVID-19). However, it remains unclear whether people living with human immunodefeciency virus (PLWH) are at an increased risk of COVID-19 and severe disease manifestation, with controversial suggestion that HIV-infected individuals could be protected from severe COVID-19 by means of antiretroviral therapy or HIV-related immunosuppression. Several cases of coinfection with HIV and SARS-CoV-2 have been reported from different parts of the globe. This review seeks to provide a holistic overview of SARS-CoV-2 infection in PLWH. © 2020 Wiley Periodicals LLCen
dc.format.mimetypeapplication/pdfen
dc.language.isoenen
dc.publisherJohn Wiley and Sons Incen
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.sourceJ. Med. Virol.2
dc.sourceJournal of Medical Virologyen
dc.subjectANTIRETROVIRAL THERAPY/COINFECTIONen
dc.subjectCOVID-19en
dc.subjectHIVen
dc.subjectIMMUNODEFICIENCYen
dc.subjectCLINICAL FEATUREen
dc.subjectCOMORBIDITYen
dc.subjectCORONAVIRUS DISEASE 2019en
dc.subjectDISEASE ASSOCIATIONen
dc.subjectDISEASE SEVERITYen
dc.subjectHIGH INCOME COUNTRYen
dc.subjectHUMANen
dc.subjectHUMAN IMMUNODEFICIENCY VIRUS 1 INFECTIONen
dc.subjectINFECTION RISKen
dc.subjectMIXED INFECTIONen
dc.subjectNONHUMANen
dc.subjectPANDEMICen
dc.subjectREVIEWen
dc.subjectVIRUS LOADen
dc.subjectADULTen
dc.subjectCD4+ T LYMPHOCYTEen
dc.subjectDIABETES MELLITUSen
dc.subjectDRUG EFFECTen
dc.subjectFEMALEen
dc.subjectGROWTH, DEVELOPMENT AND AGINGen
dc.subjectHIGHLY ACTIVE ANTIRETROVIRAL THERAPYen
dc.subjectHUMAN IMMUNODEFICIENCY VIRUSen
dc.subjectHUMAN IMMUNODEFICIENCY VIRUS INFECTIONen
dc.subjectHYPERTENSIONen
dc.subjectIMMUNOCOMPROMISED PATIENTen
dc.subjectIMMUNOLOGYen
dc.subjectMALEen
dc.subjectMIDDLE AGEDen
dc.subjectMIXED INFECTIONen
dc.subjectMORTALITYen
dc.subjectPANDEMICen
dc.subjectPATHOGENICITYen
dc.subjectPATHOPHYSIOLOGYen
dc.subjectSURVIVAL ANALYSISen
dc.subjectTREATMENT OUTCOMEen
dc.subjectVIROLOGYen
dc.subjectANTI HUMAN IMMUNODEFICIENCY VIRUS AGENTen
dc.subjectADULTen
dc.subjectANTI-HIV AGENTSen
dc.subjectANTIRETROVIRAL THERAPY, HIGHLY ACTIVEen
dc.subjectCD4-POSITIVE T-LYMPHOCYTESen
dc.subjectCOINFECTIONen
dc.subjectCOMORBIDITYen
dc.subjectCOVID-19en
dc.subjectDIABETES MELLITUSen
dc.subjectFEMALEen
dc.subjectHIVen
dc.subjectHIV INFECTIONSen
dc.subjectHUMANSen
dc.subjectHYPERTENSIONen
dc.subjectIMMUNOCOMPROMISED HOSTen
dc.subjectMALEen
dc.subjectMIDDLE AGEDen
dc.subjectPANDEMICSen
dc.subjectSARS-COV-2en
dc.subjectSURVIVAL ANALYSISen
dc.subjectTREATMENT OUTCOMEen
dc.titleHIV/SARS-CoV-2 coinfection: A global perspectiveen
dc.typeReviewen
dc.typeinfo:eu-repo/semantics/reviewen
dc.typeinfo:eu-repo/semantics/publishedVersionen
dc.identifier.rsi45488979-
dc.identifier.doi10.1002/jmv.26321-
dc.identifier.scopus85088583592-
local.contributor.employeeKanwugu, O.N., Department of Technology for Organic Synthesis, Institute of Chemical Engineering, Ural Federal University, Yekaterinburg, Russian Federation
local.contributor.employeeAdadi, P., Department of Food Science, University of Otago, Dunedin, New Zealand
local.description.firstpage726-
local.description.lastpage732-
local.issue2-
local.volume93-
dc.identifier.wos000552989400001-
local.contributor.departmentDepartment of Technology for Organic Synthesis, Institute of Chemical Engineering, Ural Federal University, Yekaterinburg, Russian Federation
local.contributor.departmentDepartment of Food Science, University of Otago, Dunedin, New Zealand
local.identifier.pure20377699-
local.identifier.pure51bf165d-0ab5-4bcc-a955-a0fad89dc5b3uuid
local.identifier.eid2-s2.0-85088583592-
local.identifier.wosWOS:000552989400001-
local.identifier.pmid32692406-
Располагается в коллекциях:Научные публикации ученых УрФУ, проиндексированные в SCOPUS и WoS CC

Файлы этого ресурса:
Файл Описание РазмерФормат 
2-s2.0-85088583592.pdf1,12 MBAdobe PDFПросмотреть/Открыть
Показать базовое описание ресурса Статистика  Google Scholar





Все ресурсы в архиве электронных ресурсов защищены авторским правом, все права сохранены.